A cheap statin halved decompensation events in a small cirrhosis trial

A six-month course of atorvastatin — one of the cheapest, most familiar cholesterol pills in medicine — sharply reduced the recurrence of serious complications in people with decompensated cirrhosis in a small randomised trial [s1][s2]. The effect size was large and the drug is already everywhere, which makes the finding genuinely interesting; but the trial was single-centre and modest in size, so it belongs in the "promising, unproven" column rather than the "practice-changing" one [s1].

Decompensated cirrhosis is the stage at which a scarred liver starts to fail visibly — fluid in the abdomen, confusion, bleeding, kidney failure — and each new complication worsens the odds [s1]. Once a patient reaches that stage, the mainstays of care are supportive, and the only definitive treatment is a transplant, which most patients will never receive [s1]. Statins have drawn interest in liver disease for reasons beyond cholesterol: in the laboratory they calm inflammation and may ease the high pressure in the portal vein that drives much of the damage [s1]. Several observational studies have hinted at a survival advantage, but association is not proof, and this trial was designed to test the idea head-on [s1].

What the trial did

The trial was randomised, double-blind and placebo-controlled, conducted at a single centre and funded by Tanta University rather than a drug company [s1][s2]. One hundred adults with decompensated cirrhosis were assigned 1:1 to either atorvastatin at 20 mg a day or a matching placebo for six months, on top of standard care [s1]. The primary endpoint was the incidence of recurrent decompensation events — new episodes of the complications that define the condition [s1]. Secondary measures tracked blood markers of oxidative stress, systemic inflammation, gut-barrier leakiness and endotoxin exposure, the biological pathways through which a statin might act [s1].

What it found

The difference on the main endpoint was substantial. Over six months, 36% of patients on atorvastatin had a recurrent decompensation event, compared with 72% on placebo — a hazard ratio of 0.50 (95% CI 0.33 to 0.75; P<0.001) [s1]. The drug also appeared to protect against hepatorenal syndrome, a dangerous form of kidney failure in advanced liver disease: no one in the atorvastatin group developed it, versus 20% in the placebo group (all type 2) [s1]. Those clinical signals were mirrored by falls in markers of oxidative stress, inflammation, endotoxin and intestinal permeability (P<0.05), consistent with the idea that the statin acts by calming the inflamed, leaky gut-liver axis rather than through cholesterol lowering [s1]. Tolerability was good overall, though mild muscle pain was more common on the statin (14% versus 2%), and the transient rises in liver enzymes the authors saw were judged clinically unimportant [s1].

How to read it

Taken at face value, halving the recurrence of decompensation with a generic pill would be a big deal in hepatology, where options are limited and expensive [s1]. The biological story is coherent, the trial was blinded and placebo-controlled, and the funding was academic rather than commercial, which removes one common source of bias [s1]. But size is the governing caveat: 100 patients at one centre is a small foundation for an effect this large, and small trials systematically overstate benefits, partly because a dramatic early result is more likely to be published and partly through the play of chance [s1]. The apparent total protection against hepatorenal syndrome, in particular, rests on small numbers and should be read as a hypothesis, not a guarantee — a zero in one arm of a 50-person group can turn into a handful of cases in a larger trial [s1].

There are the usual single-centre questions, too — whether the patient mix, background care and follow-up would look the same elsewhere — and a six-month window that leaves the durability of the benefit, and any effect on survival, untested [s1]. The authors themselves call for larger, multicentre confirmation before the approach is adopted broadly, and that caution is appropriate [s1].

What to watch

The real test will be a larger, multicentre trial powered for hard outcomes such as death and transplant-free survival, ideally long enough to show whether the early reduction in complications persists [s1]. If it holds, a drug that costs pennies could become a genuine addition to the care of a disease with few affordable options — but that "if" is doing a lot of work until the evidence is bigger [s1][s2].

This article describes research and is not medical advice. Starting or stopping a statin in liver disease is a decision for treating clinicians.

Sources

• Atorvastatin reduces recurrent decompensation events in advanced cirrhosis — Scientific Reports, 21 March 2026
• Trial registration, NCT05563389 — ClinicalTrials.gov